Announced details
Combination treatment with chemoradiotherapy for esophageal cancer, particularly in patients with esophageal cancer who are unable to undergo surgery
Clinical complete response rate: 100% among 13 patients evaluable for efficacy and 87% among all 15 enrolled patients. One-year overall survival rate: 60%; progression-free survival rate: 53%. Severe adverse events: neutropenia, 40%; lymphopenia, 33%.
15 patients enrolled in NRG-GI007, 14 received OBP-301, and 13 were evaluable for efficacy
The organization responsible for conducting the NRG-GI007 clinical trial using the company's proprietary OBP-301. Capital and personnel relationships: not disclosed.
A clinical trial group supported by the U.S. National Cancer Institute. It is described as one of the world's largest and most prestigious clinical trial groups.
No impact on the financial results for the fiscal year ending December 2026
The company does not address Contract Value / Offering price.
Paper published in the International Journal of Radiation Oncology・Biology・Physics; NRG-GI007
| Item | Details |
|---|---|
| Names of Products / Services Covered | OBP-301, Telomelysin (development code: OBP-301) |
| Counterparty | NRG Oncology |
| Counterparty overview | A clinical trial group supported by the U.S. National Cancer Institute. It is described as one of the world's largest and most prestigious clinical trial groups. |
| Relationship with the Company | The organization responsible for conducting the NRG-GI007 clinical trial using the company's proprietary OBP-301. Capital and personnel relationships: not disclosed. |
| Launch date | June 2020 (trial start; actual) |
| Applicable area | Combination treatment with chemoradiotherapy for esophageal cancer, particularly in patients with esophageal cancer who are unable to undergo surgery |
| Quantitative Effects | Clinical complete response rate: 100% among 13 patients evaluable for efficacy and 87% among all 15 enrolled patients. One-year overall survival rate: 60%; progression-free survival rate: 53%. Severe adverse events: neutropenia, 40%; lymphopenia, 33%. |
| Usage history | 15 patients enrolled in NRG-GI007, 14 received OBP-301, and 13 were evaluable for efficacy |
| Impact on Business Performance | No impact on the financial results for the fiscal year ending December 2026 |
| Source | Paper published in the International Journal of Radiation Oncology・Biology・Physics; NRG-GI007 |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The results of the NRG-GI007 trial were published in an international medical journal. The company states that its future development strategy will be determined through discussions with specialists in Japan, taking the trial results into account.